Study shows AstraZeneca's Covid-19 mAb Evusheld may not work against dominant Omicron strain

AstraZeneca’s prophylactic treatment for Covid-19, known as Evusheld, has survived where other mAbs failed, showing efficacy for the immunocompromised and others who cannot be vaccinated across multiple variants, including Delta and several Omicron subvariants.